Introduction Of New Advate Convenience Features For Plasma-albumin-free Haemophilia A Therapy

COMPTON, England - Baxter Healthcare Ltd announced today the introduction of BAXJECT II, an innovative needle-less reconstitution device and an improved packaging design for its plasma-albumin-free haemophilia A therapy ADVATE. Introduction of these two new convenience features has just started and patients will begin to receive them in the coming weeks.


BAXJECT II is an advanced needle-less reconstitution device, designed to offer the enhanced convenience and safety advantages of a needle-free system, together with fast and easy reconstitution.


"We listened carefully to our ADVATE users and their caregivers on how to further improve the ease of infusion, and are proud to introduce BAXJECT II," said Alton Shader, Vice President of Marketing, Baxter Europe. "This device, and the new packaging, underscores Baxter's commitment and continued investment to improve convenience and enhance the quality of life of haemophilia patients and their families."


BAXJECT II enhances convenience for patients by allowing ADVATE reconstitution in a few fast and simple steps. Unlike already commercially available integrated syringe systems, BAXJECT II includes a particle filter contributing to ADVATE's safety concept and allowing patients to use a butterfly infusion set of their choice. In addition BAXJECT II allows patients, who need higher doses, to draw multiple vials into one syringe.


BAXJECT II will be introduced in combination with a new packaging that consists of two small boxes instead of one larger box. All ancillaries required for administration are now supplied in the second, separate small box, which can be detached and stored outside the refrigerator.


About Haemophilia A


Haemophilia and related bleeding disorders are lifelong inherited conditions in which an essential blood-clotting factor is either partly or completely missing or faulty. The most common form of haemophilia is called Haemophilia A and in this case clotting factor VIII is faulty or missing. Treatment usually involves replacing the missing clotting factor with regular infusions. If left untreated, internal bleeding causes acute pain and long-term joint damage.


About ADVATE


ADVATE is a blood clotting therapy that helps people with haemophilia A prevent and control bleeding episodes. Infused directly into the bloodstream, ADVATE works by temporarily raising the level of factor VIII in the blood, thus allowing the body's blood clotting process to function properly.


ADVATE the first and only factor VIII haemophilia therapy made without the addition of any human or animal plasma proteins, thereby virtually eliminating the risk for transmission of infections caused by pathogens that could be carried with these plasma protein additives.


ADVATE is processed by Baxter in its state-of-the-art, multi-purpose, biotechnology facility in Neuchвtel, Switzerland. This facility has the capacity to help ensure sufficient supplies of this therapy based on current and anticipated patient needs.


About Baxter


Baxter Healthcare Ltd. is the primary domestic operating subsidiary of Baxter International Inc. (NYSE: BAX). Baxter International Inc., through its subsidiaries, assists health-care professionals and their patients with treatment of complex medical conditions, including cancer, haemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.


Baxter, and ADVATE are trademarks of Baxter International Inc.


Baxter

Wallingford Road

Compton

Newbury

Berkshire RG20 7QW

UK

Baxter Healthcare UK

Baxter Healthcare Corporation

advate